Gland Pharma Limited (GLAND) — Financial Flexibility Index
Gland Pharma Limited (GLAND) has a Financial Flexibility Index of 0.35x as of September 2025. Free cash flow of Rs7.87 Billion (operating CF Rs5.93 Billion minus capex Rs1.94 Billion) represents 0% of total liabilities (Rs22.37 Billion). Check how aggressively does Gland Pharma Limited reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Gland Pharma Limited Financial Flexibility Index (2017–2026)
Historical Financial Flexibility Index trend for Gland Pharma Limited across 10 annual periods. For the full cash flow conversion analysis, see Gland Pharma Limited (GLAND) cash flow conversion.
Annual Financial Flexibility Index for Gland Pharma Limited (2017–2026)
Year-by-year free cash flow to debt coverage for Gland Pharma Limited. Explore GLAND operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (INR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2026 | 0.80x | Rs17.22 Billion | Rs12.31 Billion | Rs21.53 Billion | ▲ +27.7% |
| 2025 | 0.63x | Rs12.99 Billion | Rs9.15 Billion | Rs20.74 Billion | ▼ -12.5% |
| 2024 | 0.72x | Rs13.87 Billion | Rs9.97 Billion | Rs19.37 Billion | ▼ -0.2% |
| 2023 | 0.72x | Rs5.87 Billion | Rs3.64 Billion | Rs8.19 Billion | ▼ -63.1% |
| 2022 | 1.94x | Rs13.13 Billion | Rs7.91 Billion | Rs6.76 Billion | ▲ +38.1% |
| 2021 | 1.41x | Rs8.34 Billion | Rs6.05 Billion | Rs5.93 Billion | ▼ -30.9% |
| 2020 | 2.04x | Rs8.96 Billion | Rs7.01 Billion | Rs4.40 Billion | ▲ +319.7% |
| 2019 | 0.49x | Rs3.21 Billion | Rs1.85 Billion | Rs6.62 Billion | ▼ -12.3% |
| 2018 | 0.55x | Rs2.87 Billion | Rs2.02 Billion | Rs5.19 Billion | ▼ -64.1% |
| 2017 | 1.54x | Rs5.93 Billion | Rs4.76 Billion | Rs3.84 Billion | — |